Synthesis of Protein Kinase Inhibitors
a Sicor S.r.l., Rho, Italy, b Teva Czech Industries s.r.o., Opava, Czech Republic
Two procedures have been developed for the synthesis of sorafenib tosylate. The aim of the development was to minimize production of symmetric ureas in the course of synthesis, which create the major impurities of the preceeding processes and are difficult to remove. The major achievements were the purity of sorafenib thus obtained (< 99.8 %, HPLC) and possibility to scale up the syntheses.
Full text (PDF)